ROS Therapeutics ApS: Financial statements 2023
CVR: 39507501
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ROS Therapeutics ApS (CVR 39507501) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -677,648 and a net result of DKK -1,152,395 compared with DKK -3,350,372 the year before. Equity in the 2023 report amounted to DKK -5,260,806. The company had 1 employee in the financial year.
- Gross Profit
- DKK -677,648
- Profit/Loss
- DKK -1,152,395
- Equity
- DKK -5,260,806
- Total Assets
- DKK 1,907,392
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -678 t. | -1.2 mio. | -5.3 mio. | 1 |
| 2022 | - | -3.1 mio. | -3.4 mio. | -4.1 mio. | 1 |
| 2021 | - | -4.8 mio. | -4.4 mio. | -758 t. | 1 |
| 2020 | - | -2 mio. | -1.9 mio. | 3.6 mio. | 1 |
| 2019 | - | -2.1 mio. | -1.9 mio. | 5 mio. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ROS Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -3,096,334, and the net result was DKK -3,350,372.
About ROS Therapeutics ApS
ROS Therapeutics ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2018. The company is in liquidation. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hanne Damgaard Jensen. The company is owned by Sandlykke A/S, HDJ & LEJ Invest ApS and ROS Therapeutics Holding ApS. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -543,530 and a net result of DKK -1,212,924 compared with DKK -1,314,915 the year before. Equity in the 2025 report amounted to DKK -7,954,408.